Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

LianBio Receives $465 Million Cash Buyout Plus Contingent Rights Offer From Tang Capital

publication date: Dec 1, 2023

LianBio, a Princeton-Shanghai in-licensing company, received a $465 million buyout offer from Tang Capital Management of San Diego. In addition, Tang also offered shareholders a contingent value right (CVR) for 80% of net proceeds from any license or divestment of a LianBio holding. The offer is Tang’s fifth takeover target this year. The previous four companies have been biopharmas that are close to going out of business, while LianBio is in better shape. Recently, LianBio signed a deal worth $350 million upfront for China rights for mavacamten, a cardiomyopathy drug, to BMS, which already owned rest-of-the-world rights. More details...

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here